Suzanne J. Randle

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk

Roger B. Dodd, Masahiro Enomoto, Ye Zhou, Kanayo Satoh et autres

ABSTRACT We report the results of structural, functional and genetic studies on the CD33 sialic acid- binding receptor that reveal how non-coding variants in CD33 alter risk for Alzheimer’s disease (AD). The full-length CD33 M isoform, whose expression is upregulated by non-coding …

gb, ca, us, il, au (code pays fourni par la source)

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk.

Roger Dodd, Masahiro Enomoto, Ye Zhou, Kanayo Satoh et autres

Supplementary Figure 2 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 2. Cell viability values at clinically relevant concentrations of capivasertib and T-DXd.

Supplementary Figure 7 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 7. Western blot analysis of NCI-N87 cells treated with capivasertib, T-DXd monotherapy or the combination.

Supplementary Figure 11 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 11. Individual animals plots for breast, ovarian and endometrial xenograft models treated with T-DXd, capivasertib or the combination.

Supplementary Table 2 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Table 2. Antibody details

Supplementary Figure 16 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 16. In vitro activity of capivasertib plus T-DXd in cell lines used for in vivo studies

Supplementary Figure 8 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 8. Active cell cycle distribution analysis of KPL4, EFM19 and KPL4 cells treated with T-DXd or capivasertib monotherapy, or the combination

Supplementary Figure 14 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 14. Aligning mouse and human pharmacokinetic profiles for T-DXd

Supplementary Table 5 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Table 5. Summary of TGI for all in vivo studies

Supplementary Figure 1 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 1. Capivasertib plus T-DXd combination treatment activity in breast and gastric cell lines.

Supplementary Figure 13 from Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors

Azadeh Cheraghchi-Bashi, Theresa A. Proia, Mandy Lawson, Anders R. Nelson et autres

Supplementary Figure 13. Body weight of animals in anti-tumour studies.